Novo Nordisk's new Boston-area campus reflects 'competitive' R&D growth, and not just for GLP-1s

The weather in Lexington, Massachusetts, may have been rainy and dreary Wednesday, but the mood inside Novo Nordisk’s new U.S. R&D homebase was anything but.

Scientists, stakeholders, executives and politicians piled into the old Dicerna facility, which has been under Novo ownership since the Danish pharma bought the biotech for $3.3 billion back in 2021. Wednesday’s event marked the formal unveiling of the redesigned facility, which solidifies the Boston area as Novo’s companion headquarters alongside Copenhagen.